Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427958 | PMC |
| http://dx.doi.org/10.1186/s13075-021-02601-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chapter 12: PREPARATION FOR PARATHYROID SURGERY.
Ann Endocrinol (Paris)
January 2025
Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, AP-HP, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphate, 94 275 Le Kremlin Bicêtre, France. Electronic address:
Preoperative treatment of PHPT aims to 1) manage severe and/or symptomatic hypercalcemia and 2) prevent postoperative hypocalcemia. Severe hypercalcemia, defined as a blood calcium level ≥ 3.5 mmol/L, requires admission to hospital in a conventional or critical care unit, depending on clinical symptoms and comorbidities.
View Article and Find Full Text PDFExploration of factors affecting denosumab-induced hypocalcemia in male patients with osteoporosis using a hospital-based administrative claims database.
Maturitas
December 2024
Division of Drug Informatics, Keio University Faculty of Pharmacy, Graduate School of Pharmaceutical Sciences, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan. Electronic address:
Objectives: Factors affecting denosumab-induced hypocalcemia in male patients with osteoporosis remain unclear because of the small patient population. Nevertheless, it is important to explore male-specific risk factors. This study aimed to identify the factors affecting the development of denosumab-induced hypocalcemia in male patients with osteoporosis and compare them with those in female patients with osteoporosis.
View Article and Find Full Text PDFCorrection: Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials.
Arch Osteoporos
November 2024
College of Pharmacy, Guizhou Medical University, Guiyang, Guizhou, China.
Association of Delayed Denosumab Dosing with Increased Risk of Fractures: A Population-Based Retrospective Study.
Endocrinol Metab (Seoul)
December 2024
Health Insurance Review & Assessment Service, Wonju, Korea.
Article Synopsis
- Delayed administration of denosumab, a treatment for osteoporosis, increases fracture risk among women aged 45 to 89 years based on a nationwide study.
- * The study found that fractures were significantly more common in participants who had delayed doses, especially those who delayed for 3 months or more.
- * Emphasizing the importance of adhering to the prescribed dosing schedule is critical to reduce the risk of fractures in patients on denosumab.
A Multi-Center Observation Study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in Patients with Osteoporosis, and Other Non-Malignant Bone Diseases, in Northwestern Italy over 16 Years.
Biomedicines
September 2024
Oncology Unit, DAIRI Department, Azienda Ospedaliera Universitaria "SS Antonio e Biagio e C. Arrigo", 15121 Alessandria, Italy.
Article Synopsis
- The study aimed to assess the rise in new cases of Medication-Related Osteonecrosis of the Jaw (MRONJ) among patients with osteoporosis and other non-cancerous bone diseases in Northwestern Italy from 2007 to 2022.
- Researchers analyzed 198 MRONJ cases, finding that the majority were linked to osteoporosis and primarily involved treatments with bisphosphonates.
- The findings revealed a significant increase in new MRONJ cases over the years, with a call for better collaboration among healthcare specialists for early detection and improved patient outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!